{
  "approved_at_utc": null,
  "subreddit": "stocks",
  "selftext": "Big news in the medical field today as Intellia Therapeutics and Regeneron announce, for the first time, history-making news that they have successfully treated a genetic disease, ATTR amyloidosis, with a single infusion of CRISPR, a programmable gene editing tool. This data was also published in the premiere medical journal, NEJM\n\nhttps://ir.intelliatx.com/news-releases/news-release-details/intellia-and-regeneron-announce-landmark-clinical-data-showing\n\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa2107454?query=featured_home\n\nFor those unaware, CRISPR is a programmable gene editing system discovered in 2012 which allows precise gene editing at a target locus. Jennifer Doudna, the founder of NTLA, and Emannuelle Charpentier, the founder of CRSP, were awarded the 2020 Nobel Prize in Chemistry.\n\nThis really demonstrates the promise of CRISPR to treat all genetic diseases. \n\nI believe this will cause the entire sector of gene editing and maybe genomics stocks to move higher. Other stocks in this field include BEAM, EDIT, VERV, VRTX, and CRSP.\n\nSome additional articles:\n\nhttps://www.npr.org/sections/health-shots/2021/06/26/1009817539/he-inherited-a-devastating-disease-a-crispr-gene-editing-breakthrough-stopped-it?fbclid=IwAR0pufLeRHs8QGStWirHjLpAyw0WF8wVnOZ-oRuHPu520tGZ4J2Scmwpxd4\n\nhttps://www.sciencemag.org/news/2021/06/crispr-injected-blood-treats-genetic-disease-first-time\n\nhttps://www.statnews.com/2021/06/26/intellia-therapeutics-ntla-2001-data/",
  "author_fullname": "t2_69ph5v0c",
  "saved": false,
  "mod_reason_title": null,
  "gilded": 0,
  "clicked": false,
  "title": "$NTLA and $REGN announce that they have successfully corrected a hereditary disease with an infusion of CRISPR",
  "link_flair_richtext": [],
  "subreddit_name_prefixed": "r/stocks",
  "hidden": false,
  "pwls": 6,
  "link_flair_css_class": null,
  "downs": 0,
  "top_awarded_type": null,
  "hide_score": false,
  "name": "t3_o8fqex",
  "quarantine": false,
  "link_flair_text_color": "dark",
  "upvote_ratio": 0.89,
  "author_flair_background_color": null,
  "subreddit_type": "public",
  "ups": 1098,
  "total_awards_received": 1,
  "media_embed": {},
  "author_flair_template_id": null,
  "is_original_content": false,
  "user_reports": [],
  "secure_media": null,
  "is_reddit_media_domain": false,
  "is_meta": false,
  "category": null,
  "secure_media_embed": {},
  "link_flair_text": null,
  "can_mod_post": false,
  "score": 1098,
  "approved_by": null,
  "is_created_from_ads_ui": false,
  "author_premium": false,
  "thumbnail": "",
  "edited": 1624730687,
  "author_flair_css_class": null,
  "author_flair_richtext": [],
  "gildings": {},
  "content_categories": null,
  "is_self": true,
  "mod_note": null,
  "created": 1624759152,
  "link_flair_type": "text",
  "wls": 6,
  "removed_by_category": null,
  "banned_by": null,
  "author_flair_type": "text",
  "domain": "self.stocks",
  "allow_live_comments": false,
  "selftext_html": "<!-- SC_OFF --><div class=\"md\"><p>Big news in the medical field today as Intellia Therapeutics and Regeneron announce, for the first time, history-making news that they have successfully treated a genetic disease, ATTR amyloidosis, with a single infusion of CRISPR, a programmable gene editing tool. This data was also published in the premiere medical journal, NEJM</p>\n\n<p><a href=\"https://ir.intelliatx.com/news-releases/news-release-details/intellia-and-regeneron-announce-landmark-clinical-data-showing\">https://ir.intelliatx.com/news-releases/news-release-details/intellia-and-regeneron-announce-landmark-clinical-data-showing</a></p>\n\n<p><a href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa2107454?query=featured_home\">https://www.nejm.org/doi/full/10.1056/NEJMoa2107454?query=featured_home</a></p>\n\n<p>For those unaware, CRISPR is a programmable gene editing system discovered in 2012 which allows precise gene editing at a target locus. Jennifer Doudna, the founder of NTLA, and Emannuelle Charpentier, the founder of CRSP, were awarded the 2020 Nobel Prize in Chemistry.</p>\n\n<p>This really demonstrates the promise of CRISPR to treat all genetic diseases. </p>\n\n<p>I believe this will cause the entire sector of gene editing and maybe genomics stocks to move higher. Other stocks in this field include BEAM, EDIT, VERV, VRTX, and CRSP.</p>\n\n<p>Some additional articles:</p>\n\n<p><a href=\"https://www.npr.org/sections/health-shots/2021/06/26/1009817539/he-inherited-a-devastating-disease-a-crispr-gene-editing-breakthrough-stopped-it?fbclid=IwAR0pufLeRHs8QGStWirHjLpAyw0WF8wVnOZ-oRuHPu520tGZ4J2Scmwpxd4\">https://www.npr.org/sections/health-shots/2021/06/26/1009817539/he-inherited-a-devastating-disease-a-crispr-gene-editing-breakthrough-stopped-it?fbclid=IwAR0pufLeRHs8QGStWirHjLpAyw0WF8wVnOZ-oRuHPu520tGZ4J2Scmwpxd4</a></p>\n\n<p><a href=\"https://www.sciencemag.org/news/2021/06/crispr-injected-blood-treats-genetic-disease-first-time\">https://www.sciencemag.org/news/2021/06/crispr-injected-blood-treats-genetic-disease-first-time</a></p>\n\n<p><a href=\"https://www.statnews.com/2021/06/26/intellia-therapeutics-ntla-2001-data/\">https://www.statnews.com/2021/06/26/intellia-therapeutics-ntla-2001-data/</a></p>\n</div><!-- SC_ON -->",
  "likes": null,
  "suggested_sort": null,
  "banned_at_utc": null,
  "view_count": null,
  "archived": false,
  "no_follow": false,
  "is_crosspostable": false,
  "pinned": false,
  "over_18": false,
  "awarders": [],
  "media_only": false,
  "can_gild": false,
  "spoiler": false,
  "locked": false,
  "author_flair_text": null,
  "treatment_tags": [],
  "visited": false,
  "removed_by": null,
  "num_reports": null,
  "distinguished": null,
  "subreddit_id": "t5_2qjfk",
  "mod_reason_by": null,
  "removal_reason": null,
  "link_flair_background_color": "",
  "id": "o8fqex",
  "is_robot_indexable": true,
  "report_reasons": null,
  "author": "Social_History",
  "discussion_type": null,
  "num_comments": 10,
  "send_replies": true,
  "whitelist_status": "all_ads",
  "contest_mode": false,
  "mod_reports": [],
  "author_patreon_flair": false,
  "author_flair_text_color": null,
  "permalink": "/r/stocks/comments/o8fqex/ntla_and_regn_announce_that_they_have/",
  "parent_whitelist_status": "all_ads",
  "stickied": false,
  "url": "https://www.reddit.com/r/stocks/comments/o8fqex/ntla_and_regn_announce_that_they_have/",
  "subreddit_subscribers": 2836600,
  "created_utc": 1624740631,
  "num_crossposts": 0,
  "media": null,
  "is_video": false,
  "original_created_utc": 1624730352,
  "the_new_excerpt": "Big news in the medical field today as Intellia Therapeutics and Regeneron\nannounce, for the first time, history-making news that they have successfully\ntreated a genetic disease, ATTR amyloidosis, with a single infusion of CRISPR, a\nprogrammable gene editing tool. This data was also published in…",
  "localize": [
    {
      "locale": "ja",
      "the_new_excerpt": "Intellia Therapeutics社とRegeneron社が本日、医療分野でのビッグニュースを発表しました。\nが、遺伝子疾患であるATTRアミロイドーシスの治療に成功したという歴史的なニュースが発表されました。\n遺伝病であるATTRアミロイドーシスを、プログラム可能な遺伝子編集ツールであるCRISPRを1回の注入で治療することに成功したと発表しました。\n遺伝病であるATTRアミロイドーシスの治療に成功したことを発表しました。また、このデータは...",
      "title": "$NTLAと$REGNがCRISPRの注入で遺伝性疾患の改善に成功したと発表"
    },
    {
      "locale": "zh",
      "the_new_excerpt": "今天医学领域的重大新闻是Intellia Therapeutics公司和Regeneron公司\n首次宣布了一个创造历史的消息：他们已经成功地\n用CRISPR的单次注射治疗一种遗传性疾病--ATTR淀粉样变性。\n可编程的基因编辑工具。这一数据也被发表在...",
      "title": "$NTLA和$REGN宣布，他们已经成功地用CRISPR输液纠正了一种遗传性疾病"
    },
    {
      "locale": "zh-Hant",
      "the_new_excerpt": "今天醫學領域的重大新聞是Intellia Therapeutics公司和Regeneron公司\n首次宣佈了一個創造歷史的消息：他們已經成功地\n用CRISPR的單次注射治療一種遺傳性疾病--ATTR澱粉樣變性。\n可編程的基因編輯工具。這一數據也被髮表在...",
      "title": "$NTLA和$REGN宣佈，他們已經成功地用CRISPR輸液糾正了一種遺傳性疾病"
    }
  ],
  "source_updated_at": 1625218969049
}